Diagnostic Nuclear Medicine PET Scan 
AuntMinnie
MARCH 4, 2025
Thus, the researchers aimed to determine prospectively whether 18F-FES PET improves staging for patients with clinical stage II/III or local-regional recurrent, grade 1 or 2, ER-positive breast cancer compared with standard F-18 FDG-PET. The tumor in the right breast (T4N0M0, grade 3 ductal carcinoma) is visible on both PET scans.
AuntMinnie
APRIL 10, 2025
Over the same period between the two years, the average number of PET scans performed per installed fixed PET/CT systems increased by 8.2% -- a finding that indicates that much of the increased procedure volumes have been absorbed by existing PET system capacity. Davin Korstjens of IMV Medical Information Division.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
NOVEMBER 25, 2024
F-18 florbetaben PET scans for diagnosing Alzheimer’s disease can be reduced from 20 minutes to five minutes without losing accuracy, according to a recent study. Our findings suggest that shorter scan times are a viable and effective option for brain amyloid PET imaging in clinical settings,” the group wrote.
AuntMinnie
OCTOBER 13, 2023
Centers for Medicare and Medicaid Services (CMS) announced on October 13 that it has lifted its coverage limit of one beta-amyloid PET scan per lifetime for patients with Alzheimer’s disease. Medicare coverage decisions for amyloid PET scans will now be made by local Medicare Administrative Contractors (MACs).
AuntMinnie
JULY 10, 2024
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
AuntMinnie
FEBRUARY 19, 2024
An AI algorithm designed for brain PET imaging found a glioblastoma in a patient that had gone undetected by physicians, according to a case reported February 15 in the Journal of Nuclear Medicine. Baseline scan (A), segmentation results (B), and follow-up scan (C) from patient with molecular glioblastoma.
AuntMinnie
MARCH 26, 2024
Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. This drug relies on a gallium Ga-68, too, as a diagnostic imaging agent. It's full-spectrum, personalized care," Vroman told AuntMinnie.com.
Expert insights. Personalized for you.
283 
Let's personalize your content